In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.
暂无分享,去创建一个
Juthamas Sukbuntherng | Robert A Blake | Guangmin Li | Gerald McMahon | J. Christensen | G. Mcmahon | T. Abrams | Leslie B. Lee | Lesley J. Murray | J. Cherrington | Sheri Shirazian | E. Chan | J. Sukbuntherng | Julie M Cherrington | D. Mendel | T. J. Ngai | S. Louie | T. Miller | James G Christensen | A Douglas Laird | Guangmin Li | Li Sun | Sheri Shirazian | Todd Miller | Cho Tang | R. Blake | A. Laird | Xiaohua Xin | R. Schreck | J. Carver | K. Moss | J. Haznedar | Li Sun | C. Tang | Lesley J Murray | Tinya J Abrams | Theresa J Ngai | Sharianne G Louie | Leslie B Lee | Dirk B Mendel | Xiaohua Xin | Randall E Schreck | Jeremy Carver | Emily Chan | Katherine G Moss | Joshua O Haznedar
[1] L. Ellis,et al. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. , 2000, Anti-cancer drug design.
[2] Georg Breier,et al. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo , 1992, Nature.
[3] B. Druker,et al. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. , 2000, The Journal of clinical investigation.
[4] J. Cherrington,et al. SU6668 inhibits Flk‐1/KDR and PDGFRβ in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[5] J. Cherrington,et al. New paradigms for the treatment of cancer: the role of anti-angiogenesis agents. , 2000, Advances in cancer research.
[6] B. Kirschbaum,et al. Identification and characterization of potential new therapeutic targets in inflammatory and autoimmune diseases. , 1999, European journal of biochemistry.
[7] A. Ullrich,et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. , 1999, Cancer research.
[8] J. Cherrington,et al. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. , 2001, Blood.
[9] B. Rice,et al. In vivo imaging of light-emitting probes. , 2001, Journal of biomedical optics.
[10] J. Schlessinger,et al. Signaling by Receptor Tyrosine Kinases , 1993 .
[11] A. A. Miles,et al. Vascular reactions to histamine, histamine‐liberator and leukotaxine in the skin of guinea‐pigs , 1952, The Journal of physiology.
[12] J. Christensen,et al. High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[13] 清水 顕. The dermatofibrosarcoma protuberans-associated collagen type 1α1/platelet derived growth factor(PDGF)B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB , 2001 .
[14] J. Cherrington,et al. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[15] J. Schlessinger. Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.
[16] J. Griffin,et al. Role of FLT3 in leukemia. , 2002, Current opinion in hematology.
[17] N. Ferrara. Molecular and biological properties of vascular endothelial growth factor , 1999, Journal of Molecular Medicine.
[18] Cherrington,et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. , 2000, Cancer research.
[19] E. Sausville,et al. Selected novel anticancer treatments targeting cell signaling proteins. , 2001, The oncologist.
[20] C. Arteaga,et al. Tyrosine kinase inhibitors—ZD1839 (Iressa) , 2001, Current opinion in oncology.
[21] J. Reilly. Class III receptor tyrosine kinases: role in leukaemogenesis , 2002, British journal of haematology.
[22] K. Rubin,et al. Microvascular pericytes express platelet-derived growth factor-beta receptors in human healing wounds and colorectal adenocarcinoma. , 1993, The American journal of pathology.
[23] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[24] J. Baselga,et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] B. Druker,et al. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Cherrington,et al. SU 11248 is a novel FLT 3 tyrosine kinase inhibitor with potent activity in vitro and in vivo , 2003 .
[27] ScienceDirect. The American journal of pathology , 1925 .
[28] R. Xavier,et al. Tumor Induction of VEGF Promoter Activity in Stromal Cells , 1998, Cell.
[29] M. Heinrich,et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. , 2003, Blood.
[30] T. Sjöblom,et al. The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. , 1999, Cancer research.
[31] B. Druker,et al. STI571: a paradigm of new agents for cancer therapeutics. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.